Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,203 trials

NCT07198867
Recruiting
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 · China · 1 site
Registry update: 30 Sept 2025
NCT07673809
Recruiting
A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy
Phase 1/2 · Belarus, Russia · 6 sites
Registry update: 29 Jun 2026
NCT07142265
Recruiting
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Not applicable · Russia · 16 sites
Registry update: 10 Aug 2026
NCT06857071
Recruiting
Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention to Locate Undiagnosed Cases and Reduce HIV-related Stigma
Not applicable · South Africa · 1 site
Registry update: 13 Apr 2026
NCT06911060
Recruiting
Flaxseed Consumption on Biochemical and Quality of Life in Type 2 Diabetes
Not applicable · 1 site
Registry update: 23 Oct 2026
NCT07198529
Recruiting
OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina
Not applicable · South Korea · 1 site
Registry update: 17 Dec 2025
NCT07234656
Recruiting
Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer
Not applicable · Denmark · 3 sites
Registry update: 1 Apr 2026
NCT07051902
Recruiting
Microbiome and Atopy in Mali
Not applicable · Mali · 2 sites
Registry update: 15 Apr 2026
NCT06694727
Recruiting
A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure
Phase 3 · Denmark · 1 site
Registry update: 3 Oct 2025
NCT06625801
Recruiting
IVUS CHIP UPP Registry
Not applicable · United States · 18 sites
Registry update: 23 Sept 2026
NCT07106762
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Phase 2/3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, Switzerland, China, Czechia, Germany, Spain, France, United Kingdom, Ireland, Israel, Italy, Japan, Netherlands, Norway, Romania, Sweden, United States · 163 sites
Registry update: 29 Jul 2026
NCT07157865
Recruiting
Comparing Prism Adaptation Training With and Without TENS to Minimize Unilateral Spatial Neglect
Not applicable · United States · 1 site
Registry update: 23 Mar 2026
NCT07182721
Recruiting
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
Phase 2 · China · 1 site
Registry update: 15 Jul 2026
NCT07192614
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Phase 1/2 · Belgium, Canada, China, Spain, United Kingdom, Italy, Japan, South Korea, Netherlands, Poland, United States · 29 sites
Registry update: 2 Sept 2026
NCT07205263
Recruiting
RAINBOW-ICH Trial of AI Guided Minimally Invasive Neurosurgery for ICH
Not applicable · China · 1 site
Registry update: 8 Jan 2026
NCT07122401
Recruiting
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
Phase 3 · China · 1 site
Registry update: 5 Nov 2026
NCT07116616
Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · United States · 10 sites
Registry update: 23 Sept 2026
NCT07030920
Recruiting
Reducing Systemic Inflammation in People on Antiretroviral Therapy
Phase 2 · Canada · 1 site
Registry update: 19 Nov 2025
NCT07262788
Recruiting
A Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes
Not applicable · Denmark · 1 site
Registry update: 3 Mar 2026
NCT07285590
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Phase 2 · Spain, Portugal · 16 sites
Registry update: 16 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.